EMPLOYMENT AGREEMENTEmployment Agreement • December 4th, 2023 • FibroBiologics Inc. • Pharmaceutical preparations • Massachusetts
Contract Type FiledDecember 4th, 2023 Company Industry JurisdictionThis Employment Agreement (“Agreement”) is made this December 1, 2023 (the “Effective Date”) between FibroBiologics, Inc., a Delaware corporation (the “Company”) and Peter O’Heeron (the “Executive” and, together with the Company, the “Parties” or each individually, a “Party”).
FIBROBIOLOGICS, INC. EMPLOYMENT AGREEMENTEmployment Agreement • December 4th, 2023 • FibroBiologics Inc. • Pharmaceutical preparations • Texas
Contract Type FiledDecember 4th, 2023 Company Industry JurisdictionThis EMPLOYMENT AGREEMENT (this “Agreement”) is made effective from May 31, 2022 (the “Effective Date”) by and among FIBROBIOLOGICS, INC. (the “Company”) and Mark Andersen (“CFO”). The Company and CFO are hereinafter collectively referred to as the “Parties”, and individually referred to as a “Party”.
INTELLECTUAL PROPERTY CROSS-LICENSE AGREEMENTIntellectual Property Cross-License Agreement • December 4th, 2023 • FibroBiologics Inc. • Pharmaceutical preparations • Texas
Contract Type FiledDecember 4th, 2023 Company Industry JurisdictionThis INTELLECTUAL PROPERTY CROSS-LICENSE AGREEMENT (this “Agreement”), dated as of May 17, 2021 (the “Effective Date”), is made between SPINALCYTE LLC, a Texas limited liability company (“SpinalCyte”) and FIBROBIOLOGICS LLC, a Texas limited liability company (“FibroBiologics”). FibroBiologics and SpinalCyte are each referred to individually as a “Party” and collectively as the “Parties.”.
SUBLEASE AGREEMENTSublease Agreement • December 4th, 2023 • FibroBiologics Inc. • Pharmaceutical preparations
Contract Type FiledDecember 4th, 2023 Company IndustryTHIS SUBLEASE AGREEMENT (“Sublease”), is made by and between United Fire & Casualty Company, an Iowa corporation doing business as United Fire Group (“Sublandlord”) and FibroBiologics, Inc., a Delaware corporation (“Subtenant”), and shall be effective as of the date set forth below Landlord’s signature (“Effective Date”). Sublandlord and Subtenant collectively shall be referred to herein as “Parties”, and individually as a “Party.”
FIBROBIOLOGICS, LLC EMPLOYMENT AGREEMENTEmployment Agreement • December 4th, 2023 • FibroBiologics Inc. • Pharmaceutical preparations • Texas
Contract Type FiledDecember 4th, 2023 Company Industry JurisdictionThis EMPLOYMENT AGREEMENT (this “Agreement”) is made effective from July 20, 2021 (the “Effective Date”) by and among FIBROBIOLOGICS, LLC (the “Company”) and Hamid Khoja (“CSO”). The Company and CSO are hereinafter collectively referred to as the “Parties”, and individually referred to as a “Party”.
LICENSE AGREEMENTLicense Agreement • December 4th, 2023 • FibroBiologics Inc. • Pharmaceutical preparations
Contract Type FiledDecember 4th, 2023 Company Industry
Amendment 004 to the License Agreement Between K2 Biolabs and FibrobiologicsFibroBiologics Inc. • December 4th, 2023 • Pharmaceutical preparations
Company FiledDecember 4th, 2023 IndustryThis Amendment 004 (the “Amendment”) to the License Agreement dated 10/07/2021 (the “Original Agreement”), K2 Biolabs, LLC., a Delaware limited liability company, as Licensor (the “Licensor”), and FibroBiologics, Inc., Delaware corporation, as Licensee (the “Licensee”), and is effective on January 1st, 2023 (the “Effective Date”).
Amendment 003 to the License Agreement Between K2 Biolabs and FibrobiologicsFibroBiologics Inc. • December 4th, 2023 • Pharmaceutical preparations
Company FiledDecember 4th, 2023 IndustryThis Amendment (the “Amendment”) to the License Agreement dated 10/07/2021 (the “Original Agreement”), K2 Biolabs, LLC., a Delaware limited liability company, as Licensor (the “Licensor”), and FibroBiologics, Inc., a Texas LLC, as Licensee (the “Licensee”), and is effective on October 1st, 2022 (the “Effective Date”).
Amendment to the License Agreement Between K2 Biolabs and Ponce TherapeuticsLicense Agreement • December 4th, 2023 • FibroBiologics Inc. • Pharmaceutical preparations
Contract Type FiledDecember 4th, 2023 Company IndustryThis Amendment (the “Amendment”) to the License Agreement dated 10/07/2021 (the “Original Agreement”), K2 Biolabs, LLC., a Delaware limited liability company, as Licensor (the “Licensor”), and FibroBiologics, Inc., a Texas LLC, as Licensee (the “Licensee”), and is effective on July 1s1, 2022 (the “Effective Date”).
ENERGY RESEARCH PARK INDUSTRIAL LEASE BETWEEN UNIVERSITY OF HOUSTON SYSTEM, AS LANDLORD AND FibroBiologics, Inc., AS TENANT HOUSTON, TEXASLease Agreement • December 4th, 2023 • FibroBiologics Inc. • Pharmaceutical preparations
Contract Type FiledDecember 4th, 2023 Company IndustryThis Lease Agreement (the “Lease”) is made and entered into on this the 1st day of August , 2023 between the UNIVERSITY OF HOUSTON SYSTEM, an institution of higher education in the State of Texas (“Landlord”), and FibroBiologics, Inc., a Delaware Corporation (“Tenant”).
Amendment 002 to the License Agreement Between K2 Biolabs and FibrobiologicsLicense Agreement • December 4th, 2023 • FibroBiologics Inc. • Pharmaceutical preparations
Contract Type FiledDecember 4th, 2023 Company IndustryThis Amendment (the “Amendment”) to the License Agreement dated 10/07/2021 (the “Original Agreement”), K2 Biolabs, LLC., a Delaware limited liability company, as Licensor (the “Licensor”), and FibroBiologics, Inc., a Texas LLC, as Licensee (the “Licensee”), and is effective on August 1st, 2022 (the “Effective Date”).